01530.HK
3SBio Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 16.24
−0.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 26.9B | 17.7B | 9.1B | 7.8B | 6.9B |
| Cost of Revenue | 2.8B | 1.3B | 1.3B | 1.2B | 1.2B |
| Gross Profit | 24.1B | 16.3B | 7.8B | 6.6B | 5.7B |
| Operating Expenses | |||||
| R&D Expense | 3.0B | 1.5B | 1.3B | 794.8M | 693.2M |
| SG&A Expense | 7.8B | 4.3B | 3.9B | 3.5B | 3.0B |
| General & Admin Expense | 942.6M | 641.9M | 501.9M | 480.8M | 384.7M |
| Selling & Marketing Expense | 5.4B | 3.6B | 3.4B | 3.0B | 2.6B |
| Other Expenses | — | — | — | (98.6M) | (2.9M) |
| Total Operating Expenses | 10.8B | 5.8B | 5.2B | 4.2B | 3.7B |
| Cost and Expenses | 13.6B | 7.2B | 6.5B | 5.4B | 4.8B |
| Operating Income (EBIT) | 13.3B | 10.5B | 2.6B | 2.5B | 2.1B |
| Non-Operating | |||||
| Interest Income | 539.6M | 295.9M | 147.8M | 153.1M | 149.5M |
| Interest Expense | 73.4M | 74.4M | 190.8M | 212.3M | 102.7M |
| Net Interest Income | 394.0M | 221.5M | (43.1M) | (59.2M) | 46.7M |
| Other Non-Op Income/Expense | 177.4M | 203.3M | 69.5M | (479.9M) | 204.4M |
| Non-Operating Income (excl Interest) | 66.4M | 57.6M | 36.9M | 267.6M | 86.7M |
| EBT (Pre-Tax Income) | 13.5B | 10.7B | 2.7B | 2.0B | 2.3B |
| Income Tax Expense | 2.1B | 1.7B | 500.5M | 392.2M | 370.7M |
| Bottom Line | |||||
| Net Income | 10.6B | 8.5B | 2.1B | 1.5B | 1.9B |
| Earnings from Cont. Ops | 11.4B | 9.1B | 2.2B | 1.6B | 1.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 10.6B | 8.5B | 2.1B | 1.5B | 1.9B |
| Per Share | |||||
| Basic EPS | HK$4.30 | HK$3.43 | HK$0.86 | HK$0.62 | HK$0.78 |
| Diluted EPS | HK$4.27 | HK$3.43 | HK$0.85 | HK$0.62 | HK$0.74 |
| Revenue Per Share | HK$10.59 | HK$7.18 | HK$3.70 | HK$3.20 | HK$2.66 |
| Shares | |||||
| Basic Shares Outstanding | 2.5B | 2.5B | 2.5B | 2.4B | 2.6B |
| Diluted Shares Outstanding | 2.6B | 2.5B | 2.5B | 2.4B | 2.6B |
| Profitability Metrics | |||||
| EBITDA | 14.1B | 11.0B | 2.9B | 2.5B | 2.8B |
| D&A | 873.6M | 508.0M | 315.2M | 334.8M | 369.8M |
| EBIT | 13.2B | 10.5B | 2.6B | 2.2B | 2.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026